Trial · NCT02616146
Adverse events26
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 26
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Nervous system disorders | ENG-E2 125 μg/300 μg | 116 | 1,504 | 180 |
| other | Headache | Nervous system disorders | LNG-EE 150 μg/30 μg | 40 | 492 | 68 |
| serious | Visual acuity reduced | Eye disorders | ENG-E2 125 μg/300 μg | 0 | 1,504 | 0 |
| serious | Visual acuity reduced | Eye disorders | LNG-EE 150 μg/30 μg | 1 | 492 | 1 |
| serious | Dengue fever | Infections and infestations | ENG-E2 125 μg/300 μg | 1 | 1,504 | 1 |
| serious | Dengue fever | Infections and infestations | LNG-EE 150 μg/30 μg | 0 | 492 | 0 |
| serious | Gastrointestinal infection | Infections and infestations | ENG-E2 125 μg/300 μg | 1 | 1,504 | 1 |
| serious | Gastrointestinal infection | Infections and infestations | LNG-EE 150 μg/30 μg | 0 | 492 | 0 |
| serious | Influenza | Infections and infestations | ENG-E2 125 μg/300 μg | 0 | 1,504 | 0 |
| serious | Influenza | Infections and infestations | LNG-EE 150 μg/30 μg | 1 | 492 | 1 |
| serious | Urinary tract infection | Infections and infestations | ENG-E2 125 μg/300 μg | 1 | 1,504 | 1 |
| serious | Urinary tract infection | Infections and infestations | LNG-EE 150 μg/30 μg | 0 | 492 | 0 |
| serious | Foreign body | Injury, poisoning and procedural complications | ENG-E2 125 μg/300 μg | 1 | 1,504 | 1 |
| serious | Foreign body | Injury, poisoning and procedural complications | LNG-EE 150 μg/30 μg | 0 | 492 | 0 |
| serious | Epilepsy | Nervous system disorders | ENG-E2 125 μg/300 μg | 1 | 1,504 | 1 |
| serious | Epilepsy | Nervous system disorders | LNG-EE 150 μg/30 μg | 0 | 492 | 0 |
| serious | Syncope | Nervous system disorders | ENG-E2 125 μg/300 μg | 1 | 1,504 | 1 |
| serious | Syncope | Nervous system disorders | LNG-EE 150 μg/30 μg | 0 | 492 | 0 |
| serious | Device deployment issue | Product Issues | ENG-E2 125 μg/300 μg | 1 | 1,504 | 1 |
| serious | Device deployment issue | Product Issues | LNG-EE 150 μg/30 μg | 0 | 492 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02616146/events